Abstract:
Immunohistochemistry (IHC) of the primary breast cancer specimens are commonly used to determine / measure the Her 2/neu status of patients. Grading of immunohistochemistry (IHC) in determining HER-2/neu status of a patient is debatable because of its subjective approach. It has been depicted that 75% of the patients who do not have gene amplification by fluorescent in situ hybridization (FISH) have HER-2/neu over expression evaluated by IHCi. Extra cellular domain of HER-2/neu oncoprotein dropped into blood may be detected in the serum. A total sample of 160 cases with primary Breast cancer was prospectively studied over a period of 5 years in KIRAN, Pakistan. In the present study, we analyzed the rate of occurrence of HER-2/neu alterations by ELISA and IHC in breast carcinoma patients. Summary measures were calculated for various demographic and biochemical parameters. A correlation was calculated between tissue Her-2/neu and serum Her-2/neu using Pearson correlation and was found significant with a p value of 0.01. Thus showing that for routine diagnostics, the combination of IHC and ELISA is useful. Furthermore, ELISA can be used if the primary tissue sample is not available for predicting tissue HER-2 status and determination of serum HER2 ECD concentration in metastatic breast cancer may provide a useful index of tissue HER2 status, especially in light of its relatively easy and inexpensive methodology and the simplicity of sample collection.
Page(s):
88-91
DOI:
DOI not available
Published:
Journal: Pakistan Journal of Biochemistry and Molecular Biology , Volume: 48, Issue: 4, Year: 2015